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neck pain. METHODS: Patients were recruited by 42
general practitioners if they had been suffering from neck
pain for at least two weeks. The 183 patients were ran-
domly allocated to manual therapy (spinal mobilization,
n  60), physical therapy (exercise therapy and massage,
59), or GP care (counseling, education and medication,
n  64). Clinical outcomes included perceived recovery,
pain intensity, functional disability and quality of life
(EuroQol). Direct and indirect costs were measured by
means of cost diaries completed by patients during the in-
tervention period and the 52-week follow up. Differences
in mean costs between groups were evaluated by apply-
ing non-parametric bootstrapping techniques. RESULTS:
The total costs of the manual therapy (Euro 447) were
approximately one-third of the costs of the physical ther-
apy (Euro 1,297) and GP care (Euro 1,379). These differ-
ences were found to be statistically significant when
bootstrapping was applied. The cost-effectiveness ratios
and the cost-utility ratios showed that manual therapy
was dominant (less costly and more effective), compared
to physical therapy and GP care. The recovery rates
based on perceived recovery after 12 months were 72%
for manual therapy, 63% for physical therapy and 56%
for GP care. With regard to pain intensity and functional
disability, manual therapy was also found to be domi-
nant over time, compared to physical therapy and GP
care, for these clinical outcomes, although the differences
were small. CONCLUSIONS: This study showed that
manual therapy (spinal mobilization) is more effective
and less costly than physical therapy and GP care.
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Upon admission to a skilled nursing home facility, infor-
mation is recorded on a Minimum Data Set (MDS), a
400 item instrument used as the basis of 1) reimburse-
ment for Medicare eligible nursing home stays and 2)
care planning, survey and certification for all nursing
home stays. OBJECTIVE: To predict and evaluate vari-
ables related to hip fractures in the nursing home setting.
METHODS: Electronic MDS data was available from
200 homes for variable evaluation times. The first avail-
able Assessment Reference Date (A3A), was the baseline
for a regression of time to first fracture. Excluded were 1)
patients with a fracture having an A3A date within the
first 10 days of baseline visit, and 2) patients with 60
days of follow-up, from first to last A3A visit. Analysis
included a Kaplan-Meier curve summarizing time to frac-
ture, and a Cox Proportional Hazards regression model.
RESULTS: The initial data set included 23,045 patients.
11,465 met the inclusion criteria, and 336 of these had
fractures. Most important variables, based on the coeffi-
cient size, associated with increasing risk, were unsteady
gait, deterioration in ADL function, a hospital stay in the
last 90 days, use of full bed rails, and Alzheimer’s disease.
The risk was also higher among females and whites. The
need for full physical help while standing had a lower
risk when compared to need for less support, but this is
likely due to a lowered potential for falling, and increased
vigilance an the part of staff. “Deteriorated” ADL func-
tion had almost twice the risk when compared to “im-
proved” ADL. CONCLUSION: Unsteady gait, deteriora-
tion in ADL, use of bed rails, presence of Alzheimer’s
disease, and hospital admissions were associated with an
increased risk of hip fracture. A larger sample of fractures
would be more likely to be successful in studying addi-
tional relationships.
PAM23
VERTEBRAL FRACTURES AMONG 
GLUCOCORTICOID PATIENTS SIGNIFICANTLY 
INCREASE MEDICAL CARE COSTS
Meyer JW1, Burge RT2, Steinbuch M2
1Ingenix Pharmaceutical Services, Eden Prairie, MN, USA; 
2Procter & Gamble Pharmaceuticals, Mason, OH, USA
BACKGROUND: Previous studies have demonstrated
that high levels of glucocorticoid (GC) exposure are asso-
ciated with increased fracture risk. However, none has
reported potential cost impacts. OBJECTIVE: To esti-
mate the marginal costs from vertebral fractures among
GC patients. METHODS: Subjects 18–64 years old with
different GC exposure levels, with and without fractures,
were selected (n  50,191). GC exposure was catego-
rized into three levels: high (3 claims of continuous use
or 9.5 prednisone-equivalent mg/day), low (other GC
use), and no GC use. Fractures, comorbid conditions,
and costs were determined 15 months before and up to
3.5 years after index date. Regression models were used
to estimate the marginal effects of vertebral fractures on
pharmacy costs, medical costs and total costs. The mod-
els controlled for age, gender, pre-index date costs, GC
exposure/fracture combinations, and pre-index and new
post-index date comorbid conditions. RESULTS: Verte-
bral fractures led to significant per-member per-month
(PMPM) cost increases in each GC exposure group. Fur-
thermore, the additional increase in marginal cost from
vertebral fracture on total PMPM costs among high GC
patients versus low GC patients was 83% ($170; p 
0.001). Differential increases in pharmacy and medical
PMPM costs between high and low GC patients were
151% ($56; p  0.01) and 68% ($115; p  0.014), re-
spectively. CONCLUSIONS: Vertebral fractures were as-
sociated with increased PMPM costs, holding constant
patients’ underlying conditions. High GC patients had
greater PMPM increases from vertebral fractures com-
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pared to those with low or no GC exposure. These find-
ings provide new evidence that vertebral fractures have
substantial increases on treatment costs among GC pa-
tients. Also, greater PMPM increases from vertebral frac-
tures among high GC patients versus low GC patients
suggest vertebral fractures increase in severity with GC
exposure. These results also support the need for adju-
vant therapy to reduce fracture risk and associated mor-
bidities.
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OBJECTIVES: Estimation the cost of asthma in children
in Vladivostok. METHODS: In cost of disease we deter-
mined direct expenses: pharmacotherapy, hospital, out-
patient and emergency expenditures; indirect expenses:
disability pension, temporary invalidity of parents and
quality of child’s life with asthma in Vladivostok during
1995–1998. 645 families with asthmatic children filled in
a questionnarie. RESULTS: Family expenses on pharma-
cotherapy of asthmatic child during the 1996 year aver-
aged 1520,81 roubles (rb) ($303), in 1998—increased to
2149,45 rb at the expense of basic therapy. In 1996 di-
rect family expenses on asthmatic child was 10,98 
1,33% of annual income, in 1998—13,70  1,46% and
bulk of the expenditures was pharmacotherapy. 1159
children with asthma in 1995 had 618 cases of hospital-
ization, total duration was 16 058 days. One child with
asthma in 1995 year had 13,64  1,0 days of hospitaliza-
tion, in 1998—8,81  0,92. Volume of hospitalization
depended on heaviness of disease. In 1996 among 22 651
emergency cases in city 230 (1,02%) was to asthmatic
children. In 1998 this index was decreased to 109. In
1996 out-patient expenses one asthmatic child was
223,05  32,50 rb, in 1998—272,46  36,96 rb. In
1997–1998 expenses for allergologist and pulmonologist
are increased. In 1996 among 1028 asthmatic children 37
got disability pension (270 rb in month). Total family ex-
penses on asthmatic child in Vladivostok in 1996 was
4070,84  86,70 rb ($810,83  10,63), in 1997—
4767,58  69,94 rb ($821,99  8,46), in 1998—
4203,58  46,24 rb. In 1996 on asthmatic child in Vladi-
vostok bulk of the expenditures was hospitalization, in
1998—pharmacotherapy. CONCLUSION: Introduction
in Vladivostok in 1997–1998 the National program of
treatment asthma in children resulted in wide use of basic
therapy, increasing family expenses asthmatic child on
pharmacotherapy and decreasing municipal expenses on
hospitalization, emergency care and indirect losses of
family.
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OBJECTIVES: To identify factors associated with the in-
crease in the use of bilevel positive pressure ventilators
with timed backup in the Medicare population from
1996 through 1999. METHODS: We extracted durable
medical equipment claims for bilevel positive pressure
ventilators with and without timed backup (RAD and
RAD-timed, respectively), continuous positive airway
pressure devices (CPAP) and oxygen supplies (gas, liquid,
concentrator) from the 1994–1999 claims files for 5% of
Medicare beneficiaries, and compared disease prevalence,
oxygen use, and other factors in the different user groups.
RESULTS: Between 1994 and 1998, new use increased
for both RAD and RAD-timed devices, but was signifi-
cantly greater for the latter. Oxygen use remained rela-
tively stable among CPAP and RAD users, but increased
in RAD-timed users. RAD-timed users were more likely
than RAD users to have claims for oxygen (80% vs.
44%), or diagnoses suggesting chronic lung disease (86%
vs. 35%) in the first year of device use; RAD users were
more likely to have a diagnosis of sleep apnea/other sleep
disorder in the first year of use (73% vs. 14%). CON-
CLUSIONS: Debate continues over appropriate indica-
tions, servicing and reimbursement for respiratory assist
devices, particularly those with timed backup. RAD and
RAD-timed device users differ significantly. The high
prevalence of COPD diagnoses reflects current interest in
the use of these devices in the long-term treatment of this
disorder; other indications suggested in the literature,
such as respiratory support in neuromuscular disorders
or congestive heart failure, appeared rarely. Growth in
the use of the more costly RAD-timed devices among
oxygen users varied by region as well as by year, possibly
reflecting regional differences in coverage, medical prac-
tice or marketing. Person-level, longitudinal analysis of
claims data supports the development and implementa-
tion of coverage and payment policies, by helping to de-
lineate the demographic and clinical characteristics of
user groups.
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OBJECTIVE: The objective of this analysis was to evalu-
ate the impact of social class on correlation between the
standardized AQLQ, self-rated asthma severity and con-
